News – Emmyon, Inc. have developed Ursolyx Soft Chews, a new supplement intended to treat muscle atrophy in dogs and will launch the product at the Veterinary Meeting & Expo in Orlando, Florida, Jan. 25–29, 2025.

The companies say the chews are designed to enhance muscle function and strength in dogs that are aging, active or recovering from muscle loss, a condition that the report notes impairs activity, strength, endurance and overall health. Common causes of muscle atrophy in dogs include reduced use from arthritis, joint disease, or prolonged inactivity; neuromuscular diseases; and systemic illnesses such as cancer.

Virbac led the development in collaboration with Emmyon, and the product introduction is timed for the Veterinary Meeting & Expo presented by the North American Veterinary Community. The announcement frames Ursolyx Soft Chews as aimed at a clinical gap beyond joint support, focusing squarely on skeletal muscle health. This focus is significant as the global veterinary supplements market is projected to grow substantially, reflecting an increased awareness of non-invasive support options for pet health.

Giovanni Abruzzini, president and CEO of Virbac US, emphasized the role of muscle in overall mobility. “Of course, the joint is a critical part. But if you also think about the aging process, the muscles are probably even more important than the joints, because the skeletal muscles bring everything together,” he said. To maintain muscle health, pet owners can provide their dogs with a balanced diet rich in high-quality protein and ensure appropriate exercise.

The companies describe the chews as intended for dogs experiencing muscle atrophy and for animals needing support during recovery or sustained activity. That positioning is meant to address a range of patients veterinarians see in clinic, from older dogs with diminished muscle mass to dogs rehabilitating after injury or surgery.

Virbac and Emmyon plan to present technical details and availability at their VMX sessions in Orlando, where veterinary professionals gather to review new products and clinical approaches. The timing places the launch within the Jan. 25–29 conference window, offering clinicians an opportunity to learn about the supplement directly from company representatives. As the pet supplement market becomes increasingly significant, products like Ursolyx address a compelling need in both treatment and wellness strategies.

Developers describe Ursolyx Soft Chews as formulated to support the skeletal muscle system, with the goal of improving dogs’ activity levels and endurance. The plain aim, according to the announcement, is to complement existing strategies for preserving or rebuilding muscle mass so that animals maintain better day-to-day function.

Clinicians and clinic leadership attending the Veterinary Meeting & Expo will be able to assess product data and determine whether the supplement fits into treatment plans for patients with documented muscle loss. The product debut is positioned to reach an audience of veterinarians who manage aging and rehabilitating canine patients.

The launch follows testing and development work attributed to Virbac in partnership with Emmyon; further specifics about studies, dosing or distribution will be presented at the conference, according to the companies.

Virbac and Emmyon will make the product available for discussion and demonstration during VMX in Orlando from Jan. 25–29, 2025, where attendees can direct questions to company representatives and review the clinical material provided at the sessions.

Source

Original reporting: view the original article.